Hims & Hers Health, Inc. (HIMS)

Hims & Hers Health, Inc., launched in 2017, operates a consumer-first digital health and wellness platform that connects customers with licensed healthcare providers and with personalized prescription and non-prescription treatments. The platform includes a provider network, an electronic medical record system, digital prescriptions, cloud pharmacy fulfillment and personalization tools. Since its founding it has facilitated over fifty million telehealth consultations. Its stated mission is to help the world feel great through the power of better health.

The company offers treatments for chronic conditions, including sexual health, hair loss, hormone health, weight loss, dermatology and mental health, along with comprehensive laboratory testing. Offerings include prescription generic, brand-name and compounded medications, including certain sterile compounded medications, as well as over-the-counter drug and device products, cosmetics and supplements focused on general wellness, skincare, sexual health and hair care. Some over-the-counter products are white-labeled from manufacturers, and others were developed with manufacturers using input from the company's internal Product Research & Development team. Many offerings are sold on subscription plans with shipment cadences from 30 to 360 days. In 2025 it launched testosterone, menopause and perimenopause support offerings and comprehensive lab testing. Its roadmap targets further specialties such as sleep disorders, PTSD, fertility, diabetes, cholesterol and hypertension.

Customers purchase through the company's websites and mobile applications, and some over-the-counter products are sold through retail partnerships, in stores and online. Customers are acquired through social media, online search, television, radio, retail presence and other advertising. The company serves customers in the United States, Canada, the United Kingdom and the European Union (Germany, Ireland, France and Spain). In the U.S. and most other markets it accepts payment only from customers, not insurers or government payors, while in Canada certain offerings are subject to limited public or private drug coverage applied at the pharmacy. In February 2026 it announced a definitive agreement to acquire Eucalyptus, an Australia-based digital health company with operations in Australia, the UK, Germany, Canada and Japan, expected to close in mid-2026.

Operationally, the company owns two licensed 503A pharmacies and two UK GPhC-licensed pharmacies, a 503B compounding outsourcing facility, a peptide manufacturing facility and a laboratory testing facility. It also uses third-party Partner Pharmacies without exclusivity or minimum order requirements. Because of U.S. corporate practice of medicine rules, clinical services are delivered by Affiliated Medical Groups, which are physician-owned entities that employ or contract providers and that pay the company fixed fees for administrative services under agreements generally having initial ten-year terms. In the UK and Ireland it directly employs physicians through its Zava subsidiaries, which also have partnerships with Asda and Superdrug. In Canada it mainly engages nurse practitioners as independent contractors. It also has collaborations with U.S. health systems including Ochsner Health, Mount Sinai, Carbon Health, ChristianaCare and Hartford Healthcare for in-person care. The business is subject to extensive healthcare, telehealth, pharmacy and consumer protection regulation, including by the FDA.